These findings may have implications for EGFR-targeted treatments aimed at platelets and immune cells in sepsis, as well as in a wide range of pathophysiological conditions, including chronic inflammation, cancer, thrombosis, and vascular-related diseases. The gene discussed is EGFR; the disease is cancer.